Sign Up Now to Download a Free Research Report on
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? AEterna Zentaris, Inc.
AEterna Zentaris shares declined 22.52 percent on volume of over 4.3 million shares traded Monday to close at $2.03 a share. The company announced it has been recommended to discontinue its Phase 3 trial of its multiple myeloma treatment.
Going forward ... (see research report)
Subscribe to News Feeds